Table 3

Percent of patients who received first-line bevacizumab by selected patient characteristics

Characteristic*

Received first-line bevacizumab

(n = 110)

Unadjusted p-value#


%


Age (years)

0.007


< 55

41


55-64

32


65-74

30


≥ 75

16


ACE-27 Comorbidity Index (score)

0.831


None (0)

29


Mild (1)

30


Moderate (2)

35


Severe (3)

34


Race

0.403


Non-white

28


White

33


Gender

0.005


Female

41


Male

26


Insurance

0.005


Private

41


Public

20


Medicare + supplemental

32


Veterans Administration

21


Missing

21


Health system

0.050


Fee-for-service

35


Integrated health system

25


Geographic region

0.003


West/Midwest

23


Southern

35


Atlantic

43


Annual household income

0.127


< $20,000/year

25


≥ $20,000/year

34


Missing

30


Diagnosis of metastatic disease

0.532


Stage IV at diagnosis

30


Recurrence

35


Did anyone mention that enrollment in a clinical trial might be an option for you?

0.152


Yes

38


No

28


Missing

35


How often do you read books, magazines or newspapers?

0.111


Often

35


Rarely

24


Missing

26


After talking with your doctors about chemotherapy, how likely did you think it was that chemotherapy would have side-effects or complications?

0.133


Likely

33


Not likely

24


Missing

30


*The composition of health systems in the categorization of fee-for-services vs. integrated health systems has been previously described [8]. Comorbidity was calculated using the Adult Comorbidity Evaluation-27 (ACE-27) index [11]. The cardiovascular comorbidities were collected as a part of the ACE-27. #Unadjusted p-values for aggregate variable effects (type 3 Wald statistics).

Zafar et al. BMC Cancer 2011 11:354   doi:10.1186/1471-2407-11-354

Open Data